Free Trial

Pasithea Therapeutics (KTTAW) 10K Form and Latest SEC Filings 2026

$0.0051 0.00 (-16.39%)
As of 05/14/2026 03:30 PM Eastern

Latest Pasithea Therapeutics SEC Filings & Recent Activity

Pasithea Therapeutics (NASDAQ:KTTAW) has submitted 206+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026.

Form 4
Pasithea Therapeutics Corp. Reports Ownership Change on May. 5, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Pasithea Therapeutics Files Current Report on May. 4, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Pasithea Therapeutics Files Quarterly Report on Aug. 14, 2025

The 10-Q contains Pasithea Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Pasithea Therapeutics SEC Filing History

Browse Pasithea Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 9:20 AM
AMERIPRISE FINANCIAL INC (820027) Filed by
Pasithea Therapeutics (1841330) Subject
Form SCHEDULE 13G/A
05/05/2026 3:41 PM
Pasithea Therapeutics (1841330) Issuer
Schneiderman Daniel H (1565536) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 3:41 PM
Dumesnil Simon (1875691) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 3:42 PM
Pasithea Therapeutics (1841330) Issuer
STEINMAN LAWRENCE (1132679) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 3:42 PM
Marques Tiago (1875240) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 4:00 PM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/22/2026 1:43 PM
Funicular Funds, LP (1937147) Filed by
Pasithea Therapeutics (1841330) Subject
Form SCHEDULE 13G
04/17/2026 8:45 PM
Coastlands Capital LP (2068530) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/08/2026 7:25 PM
Opaleye Management Inc. (1595855) Filed by
Pasithea Therapeutics (1841330) Subject
Form SCHEDULE 13G
02/17/2026 1:48 PM
CVI Investments, Inc. (1649553) Filed by
Pasithea Therapeutics (1841330) Subject
Form SCHEDULE 13G/A
02/17/2026 10:36 AM
Pasithea Therapeutics (1841330) Subject
Squadron Capital Management LLC (2050709) Filed by
Form SCHEDULE 13G/A
02/12/2026 8:01 AM
Adage Capital Management, L.P. (1535978) Filed by
Pasithea Therapeutics (1841330) Subject
Form SCHEDULE 13G
01/27/2026 11:15 PM
Pasithea Therapeutics (1841330) Filer
Form EFFECT
01/26/2026 7:00 AM
Pasithea Therapeutics (1841330) Filer
Form POS AM
12/29/2025 4:00 PM
Pasithea Therapeutics (1841330) Filer
Form DEF 14A
12/19/2025 3:30 PM
Pasithea Therapeutics (1841330) Filer
Form PRE 14A
12/15/2025 7:00 AM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/08/2025 10:46 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Pasithea Therapeutics (1841330) Subject
Form SCHEDULE 13G
12/05/2025 3:10 PM
Pasithea Therapeutics (1841330) Subject
Squadron Capital Management LLC (2050709) Filed by
Form SCHEDULE 13G
12/02/2025 8:23 AM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/01/2025 7:56 AM
Marques Tiago (1875240) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 8:04 AM
Pasithea Therapeutics (1841330) Issuer
Schneiderman Daniel H (1565536) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 8:07 AM
Pasithea Therapeutics (1841330) Issuer
STEINMAN LAWRENCE (1132679) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 7:54 AM
Dumesnil Simon (1875691) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 7:51 AM
Leahy Emer (1875180) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 7:31 AM
Pasithea Therapeutics (1841330) Filer
Form 424B4
11/30/2025 11:15 PM
Pasithea Therapeutics (1841330) Filer
Form EFFECT
11/26/2025 4:04 PM
Pasithea Therapeutics (1841330) Filer
Form S-1/A
11/25/2025 3:15 PM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2025 9:50 AM
Pasithea Therapeutics (1841330) Filer
Form S-1
Registration statement under Securities Act of 1933  
11/04/2025 6:04 AM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/27/2025 4:25 PM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/27/2025 4:25 PM
Dumesnil Simon (1875691) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 4:26 PM
Leahy Emer (1875180) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 4:26 PM
Marques Tiago (1875240) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 4:26 PM
Novak Alfred J (1388862) Reporting
Pasithea Therapeutics (1841330) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 4:27 PM
Pasithea Therapeutics (1841330) Issuer
Schneiderman Daniel H (1565536) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 4:27 PM
Pasithea Therapeutics (1841330) Issuer
STEINMAN LAWRENCE (1132679) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2025 6:04 AM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2025 3:30 PM
Pasithea Therapeutics (1841330) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/03/2025 3:30 PM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad)

Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel

See how to get positioned in SpaceX before the announcement goes public
08/14/2025 2:44 PM
Pasithea Therapeutics (1841330) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/24/2025 3:20 PM
Pasithea Therapeutics (1841330) Filer
Form ARS
07/14/2025 3:30 PM
Pasithea Therapeutics (1841330) Filer
Form PRE 14A
06/20/2025 3:15 PM
Pasithea Therapeutics (1841330) Filer
Form 424B5
06/20/2025 3:20 PM
Pasithea Therapeutics (1841330) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Pasithea Therapeutics SEC Filings - Frequently Asked Questions

Pasithea Therapeutics (KTTAW) has submitted 206+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:KTTAW) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners